DIPSS scoring
Current understanding
Dynamic International Prognostic Scoring System for primary myelofibrosis. Risk stratification across diagnosis and follow-up.
Evidence log
- 2026-08-04 — Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.: Spanish national registry (n=1649, dx ≥2010) reports median OS 6.6y and 5-/10-y relative survival 68%/44% in the JAK inhibitor era, with only 25% of transplant-eligible DIPSS intermediate-2/high-risk patients transplanted — suggesting DIPSS-based referral thresholds are under-actioned in real-world practice. (novelty: 3)
Open questions
Related
Contributing findings
20th International Congress on Myeloproliferative Neoplasms - MPN Research Foundation Coverage
Approximately 2020-2021 (historical)
novelty 2
per-area 2
mentions
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
12-aug-2026
novelty 2
per-area 1
mentions
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.
04-aug-2026
novelty 3
per-area 3
strengthens
Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.
15-jul-2026
novelty 2
per-area 2
mentions
Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation.
13-jul-2026
novelty 2
per-area 2
mentions
[Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)].
17-jun-2026
novelty 2
per-area 2
strengthens
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.
16-jun-2026
novelty 3
per-area 1
mentions
Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.
06-jun-2026
novelty 3
per-area 1
mentions
Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities
28-may-2026
novelty 3
per-area 2
mentions
Myelofibrosis Prognosis and Life Expectancy
13-may-2026
novelty 1
per-area 1
mentions
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
04-mar-2026
novelty 3
per-area 1
mentions